Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0774 • ACR Convergence 2025
Longitudinal peripheral blood multi-omic profiling in at-risk individuals uncovers immune signatures and predictive models for future rheumatoid arthritis conversion
Jun Inamo¹, Aleksandra Bylinska², Miles Smith², Lauren Vanderlinden³, Christian Wright⁴, Tayte Stephens⁵, Marie Feser⁶, Christopher Striebich⁷, James O'Dell⁸, Jeffrey Sparks⁹, John Davis¹⁰, Jonathan Graf¹¹, Maureen McMahon¹², Elizabeth Solow¹³, Lindsy Forbess¹⁴, Athan Tiliakos¹⁵, David Fox¹⁶, Maria I. Danila¹⁷, Diane Lewis. Horowitz¹⁸, Jonathan Kay¹⁹, Judith James², V. Michael Holers²⁰, Kevin Deane²¹, Joel Guthridge² and Fan Zhang²², ¹University of Colorado School of Medicine, Aurora, CO, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Colorado Anschutz Medical Campus, Monument, CO, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵University of Oklahoma Health Science Center, Oklahoma City, OK, ⁶University of Colorado Anschutz Medical Campus, Aurora, CO, ⁷University of Colorado, Aurora, CO, ⁸University of Nebraska Medical Center, Omaha, NE, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Mayo Clinic, Rochester, MN, ¹¹UCSF, San Francisco, CA, ¹²UCLA David Geffen School of Medicine, Los Angeles, CA, ¹³UT Southwestern Medical Center, Dallas, TX, ¹⁴Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁵Emory University, Roswell, GA, ¹⁶University of Michigan, Dexter, MI, ¹⁷University of Alabama at Birmingham, Birmingham, ¹⁸Northwell Health, New Hyde Park, ¹⁹UMass Chan Medical School, Worcester, MA, ²⁰University of Colorado Anschutz Medical Campus, Aurora, ²¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²²The University of Colorado, Aurora, CO

Background/Purpose: Seropositive rheumatoid arthritis (RA) has an at-risk stage identifiable by elevations of antibodies to cyclic citrullinated peptide (CCP). Identifying the immunologic factors that distinguish…
Abstract Number: 0491 • ACR Convergence 2025
Association of Short Chain Fatty Acids and Diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
Kaci French¹, Luz Alvarado², Rebecca Haberman³ and Rebecca Blank³, ¹NYU Langone, New York, NY, ²NYU Langone, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Diet, the gut microbiome, and gut microbial metabolites have been implicated in rheumatoid arthritis (RA) development and modulation. Seafood based-omega-3 fatty acids modulate inflammatory…
Abstract Number: 0475 • ACR Convergence 2025
Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada
Cristiano Moura¹, Luck Lukusa², Denis Choquette³, Gilles Boire⁴, Nathalie Carrier⁵, Autumn Neville² and Sasha Bernatsky⁶, ¹Research Institute of the McGill University Health Center, Montréal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, Canada, ³Institut de Rhumatologie de Montréal, Saint-Donat-de-Montcalm, Canada, ⁴Retired, Sherbrooke, QC, Canada, ⁵Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: In April 2022, the Canadian province of Quebec introduced a mandatory non-medical switch to biosimilars for persons on bio-originators to manage healthcare costs. Our…
Abstract Number: 0458 • ACR Convergence 2025
TyG-BMI Index as a Serological Biomarker for Carotid Plaque and Cardiac Function Changes in Rheumatoid Arthritis
Rebeca L. Polina-Lugo¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Esteban C. Garza-Gonzalez⁴, Jesus Alberto Cardenas-de la Garza⁵, Iris J. Colunga-Pedraza³, Jose R Azpiri-Lopez⁶, Dionicio A. Galarza-Delgado³, Victor M Fraga-Enriquez⁷ and Diego Azamat Salcedo Almanza⁸, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁶Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁸Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: The Triglyceride-Glucose-BMI index (TyG-BMI) is a reliable method for detecting insulin resistance (IR), with effectiveness comparable to the gold standard. Elevated TyG-BMI levels have…
Abstract Number: 0440 • ACR Convergence 2025
The Painful Truth: Non-Articular Pain’s Impact on Rheumatoid Arthritis Assessment after Initiating a new DMARD for Active Disease
Charis Meng¹, Jing Song², Lutfiyya muhammad³, Caci Julia⁴, Tuhina Neogi⁵, Marcy Bolster⁶, Wendy Marder⁷, Clifton Bingham⁸ and Yvonne Lee⁹, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University Feinberg School of Medicine, Worthington, MN, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Hospital for Special Surgery, New York, ⁵Boston University School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Concord, MA, ⁷University of Michigan, Ann Arbor, MI, ⁸Johns Hopkins University, Baltimore, MD, ⁹Northwestern University, Chicago, IL
Background/Purpose: RA-related pain is typically thought of as pain in the joints. However, non-articular pain (NAP) is also common, persisting in 1/3 of patients with…
Abstract Number: 0359 • ACR Convergence 2025
“VA is a slow-moving ship, but you can steer it”: Clinician Views on Navigating Shared Decision-Making and Anticipated Use of an RA Decision Aid
Alicia Hamblin¹, Dylan Waller², Anaïs Tuepker², Catherine Nasrallah³, Alexandra Bennett², Brooke Jespersen², Joshua Baker⁴, Madhavi Valiveti⁵, gabriela Schmajuk⁶ and Jennifer Barton², ¹UCSF, San Francisco, CA, ²Center to Improve Veteran Involvement in Care (CIVIC) and VA Portland Health Care System, Portland, OR, ³University of California San Francisco (UCSF), San Francisco, CA, ⁴Corporal Michael J. Crescenz VA Medical Center (CMCVAMC) and University of Pennsylvania, Philadelphia, PA, ⁵VAMC Wilmington, Wilmington, DE, ⁶University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Shared decision-making (SDM) is the first overarching principle of the treat-to-target guidelines for rheumatoid arthritis (RA). The quality of SDM varies widely, and its…
Abstract Number: 0191 • ACR Convergence 2025
Advanced therapy use in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK
Aoibhinn Kelly¹, Maddalena Rupnik², Nasra Ahmed¹, Mrinalini Dey³ and Elena Nikiphorou⁴, ¹King's College Hospital NHS Foundation Trust, London, United Kingdom, ²Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴King's College London, London, United Kingdom
Background/Purpose: Moderate disease in rheumatoid arthritis (RA) is defined as a 28-joint disease activity score (DAS28) of 3.2-5.1(MDAS). As per the National Institute for Health…
Abstract Number: 0096 • ACR Convergence 2025
GLUT1-Dependent Targeting and Enhanced Selectivity of a Glucose-Methotrexate Conjugate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Sebastian Makuch¹, Jacek Polański¹ and Wojciech Tański², ¹Wrocław Medical University, Wrocław, Poland, ²Wrocław University of Science and Technology, Wrocław, Poland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease where fibroblast-like synoviocytes (FLS) play a central role in joint inflammation and destruction. Methotrexate (MTX), a…
Abstract Number: 0076 • ACR Convergence 2025
Antibodies to malondialdehyde-acetaldehyde are associated with circulating inflammatory mediators during the preclinical stages of rheumatoid arthritis
Emma Weis¹, Harlan Sayles¹, Geoffrey Thiele¹, Samir Rachid Zaim², Tony Merriman³, Bryant England¹, Xiaojun Li², LauraKay Moss⁴, Jess Edison⁵, Marie Feser⁴, V. Michael Holers⁶, Kevin Deane⁷, Ted Mikuls¹ and Austin Wheeler¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Allen Institute for Immunology, Seattle, WA, ³University of Alabama at Birmingham, Homewood, AL, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD, ⁶University of Colorado, Denver, CO, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO
Background/Purpose: Circulating concentrations of anti-malondialdehyde-acetaldehyde (MAA) antibodies distinguish patients with RA and are detectable years prior to arthritis onset. Recent data demonstrate that anti-MAA antibodies…
Abstract Number: 0055 • ACR Convergence 2025
TCR Signaling Thresholds Govern Anergy and Tolerance in ZAP70 Hypomorphic Models of Autoimmune Arthritis
Yuka Nakao, Astha Patel, Letitia Yang, Steven yu, Arthur Weiss and Judith Ashouri, University of California, San Francisco, San Francisco, CA
Background/Purpose: T cell receptor (TCR) signaling strength is a key determinant of immune tolerance and autoimmunity, yet the threshold needed to prevent pathogenic self-reactivity remains…
Abstract Number: 2684 • ACR Convergence 2025
Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis
Lilla Gunkl-Tóth¹, Gergely Orsi², Noémi Császár-Nagy³, Lili Duzsik⁴, Gábor Mátay⁴, Gábor Kumánovics⁵, Gábor Sütő², Krisztina Csókási², Szabolcs Takács⁶, Zoltán Vidnyánszky⁷, József Kun², Krisztina Takács-Lovász², Gellért Karvaly⁸, Róbert Farkas⁸, Anett Pintér⁸, Panna Királyhidi⁸, György Nagy⁸ and Zsuzsanna Helyes², ¹Semmelweis University, Budapest, Budapest, Hungary, ²University of Pécs, Pécs, Hungary, ³National University of Public Services, Budapests, Hungary, ⁴Psychosomatic Outpatient Clinic, Budapest, Hungary, ⁵University of Pecs, Pecs, Hungary, ⁶Károli Gáspár University, Budapest, Hungary, ⁷Brain Imaging Centre, Research Centre for Natural Sciences, Budapest, Hungary, ⁸Semmelweis University, Budapest, Hungary
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 5–20% of patients experience persistent symptoms, particularly pain, and are classified as difficult-to-treat (D2T). Factors such as…
Abstract Number: 2612 • ACR Convergence 2025
Automated, Artificial Intelligence-supported Sonographic Examination of the Hands for the Detection and Quantification of Arthritis and Osteoarthritis in the Hand and Finger Joints in Outpatient Rheumatology Care
Oliver Sander¹, Lea Ormeloh¹, Laura Grünkewitz¹, Martin Gallmann¹, Benedict Blümel¹, Rishi Adhikari¹, Hasan Acar¹, Gamal Chehab¹, Jörg Distler² and Jutta Richter³, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ²University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ³Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Düsseldorf, Germany
Background/Purpose: The integration of artificial intelligence (AI) in combination with robotics into clinical diagnostics has the potential to increase precision and efficiency and relieve increasingly…
Abstract Number: 2285 • ACR Convergence 2025
Synovium-on-a-chip – Development of a Humanized Rheumatoid Arthritis Model that Mimics Disease and Patient Biological Heterogeneity
Theresa Wampler Muskardin¹, Ruiqi Chen², Yeji Lee³, Azka Ali³, Andrra Nimoni³, Christele Felix³, Hattie Heiland³, Romy Kallas³, Daniel Ramirez⁴, David Mayman³, Timothy Niewold⁵ and Weiqiang Chen⁶, ¹Hospital for Special Surgery and Weill Cornell Medicine, New York, NY, ²New York University - Tandon School of Engineering, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, New York, ⁶New York University, Tandon School of Engineering, New York, NY
Background/Purpose: In rheumatoid arthritis (RA), reasons for treatment resistance and alternate strategies that would be more effective in treatment-resistant patients remain unknown. Accurate methodology to…
Abstract Number: 2267 • ACR Convergence 2025
Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
Chris Edwards¹, Janet Pope², Joelle Monnet³ and Maria Romanova Michailidi⁴, ¹University Hospital Southampton, Southampton, United Kingdom, ²University of Western Ontario, London, ON, Canada, ³Fresenius Kabi SwissBioSim, Eysins, Switzerland, ⁴University of Geneva, Eysins, Switzerland
Background/Purpose: RA has been associated with an increase risk of cardiovascular morbidity and mortality1. The present analysis was performed to assess the efficacy (on ACR…
Abstract Number: 2251 • ACR Convergence 2025
Dual Diagnoses, Diminished Survival: Association between rheumatoid arthritis and survival among older adults with lung cancer
Michelle Nguyen¹, Aaron Baraff², Alexandra Schmidt², Alexander Peterson², Aliyah Pabani³, Nicholas Smith¹, Shelly Gray¹, Jose Garcia⁴, Noel Weiss¹ and Namrata Singh⁵, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³Johns Hopkins, Washington, DC, ⁴VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁵University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of malignancies, particularly lung cancer, relative to the general population1. However, the association between RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].